Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Business Strategies Neurology

The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement

Science, Data Form Backbone

  • Interviews

Executive Summary

ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.

You may also be interested in...



Korea 2024 Outlook: Continued Focus On Drug Delivery Technologies

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.

Will The Dark Tunnel For Korean Biopharmas End In 2023?

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma

German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.

Table

View full table

Topics

Related Companies

Tags:
South Korea Business Strategies Neurology
Latest Headlines

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Falling Sales Force New Priorities At Roche

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

See All
UsernamePublicRestriction

Register

SC145903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By